Syndax Pharmaceuticals (SNDX) Cost of Revenue (2024 - 2026)

Syndax Pharmaceuticals' Cost of Revenue history runs 3 years deep, the most recent figure standing at $11.8 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 1238.53% year-over-year to $11.8 million; the TTM figure through Mar 2026 stood at $31.0 million (up 433.12% YoY), while the FY2025 annual figure was $33.8 million, up 585.17% from the prior year.
• Cost of Revenue was $11.8 million for Q1 2026 at Syndax Pharmaceuticals, up from $9.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $11.8 million in Q1 2026 to a low of $885000.0 in Q1 2025.
• Historically, Cost of Revenue has averaged $6.1 million across 3 years, with a median of $6.6 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Cost of Revenue surged 94.58% in 2025, then jumped 1238.53% in 2026.
• A 3-year view of Cost of Revenue shows it stood at $4.9 million in 2024, then surged by 94.58% to $9.6 million in 2025, then grew by 23.49% to $11.8 million in 2026.
• The last three Cost of Revenue figures came in at $11.8 million (Q1 2026), $9.6 million (Q4 2025), and $8.3 million (Q3 2025), per Business Quant data.